37 related articles for article (PubMed ID: 22009787)
1. Oral leukoplakia classification and staging system with incorporation of differentiated dysplasia.
Brouns ER; Evren I; Wils LJ; Poell JB; Brakenhoff RH; Bloemena E; de Visscher JGAM
Oral Dis; 2023 Oct; 29(7):2667-2676. PubMed ID: 35765231
[TBL] [Abstract][Full Text] [Related]
2. Implication of TIPE2 Expression on the Malignant Transformation of Oral Leukoplakia.
Chen H; Pei M; Shin SW; Moon S; Nam W; Zheng Z
Anticancer Res; 2023 Nov; 43(11):4937-4946. PubMed ID: 37909982
[TBL] [Abstract][Full Text] [Related]
3. Oral tongue leukoplakia: analysis of clinicopathological characteristics, treatment outcomes, and factors related to recurrence and malignant transformation.
Yang SW; Lee YS; Chang LC; Yang CH; Luo CM; Wu PW
Clin Oral Investig; 2021 Jun; 25(6):4045-4058. PubMed ID: 33411001
[TBL] [Abstract][Full Text] [Related]
4. The value of regular follow-up of oral leukoplakia for early detection of malignant transformation.
Evren I; Najim AM; Poell JB; Brouns ER; Wils LJ; Peferoen LAN; Brakenhoff RH; Bloemena E; van der Meij EH; de Visscher JGAM
Oral Dis; 2023 Nov; ():. PubMed ID: 37936517
[TBL] [Abstract][Full Text] [Related]
5. Tumor microenvironment - Unknown niche with powerful therapeutic potential.
Kolenda T; Przybyła W; Kapałczyńska M; Teresiak A; Zajączkowska M; Bliźniak R; Lamperska KM
Rep Pract Oncol Radiother; 2018; 23(3):143-153. PubMed ID: 29760589
[TBL] [Abstract][Full Text] [Related]
6. Markers of Oral Lichen Planus Malignant Transformation.
Tampa M; Caruntu C; Mitran M; Mitran C; Sarbu I; Rusu LC; Matei C; Constantin C; Neagu M; Georgescu SR
Dis Markers; 2018; 2018():1959506. PubMed ID: 29682099
[TBL] [Abstract][Full Text] [Related]
7. Salivary extracellular vesicle-associated miRNAs as potential biomarkers in oral squamous cell carcinoma.
Gai C; Camussi F; Broccoletti R; Gambino A; Cabras M; Molinaro L; Carossa S; Camussi G; Arduino PG
BMC Cancer; 2018 Apr; 18(1):439. PubMed ID: 29669525
[TBL] [Abstract][Full Text] [Related]
8. Targeting of chemoprevention to high-risk potentially malignant oral lesions: challenges and opportunities.
Martinez VD; MacAulay CE; Guillaud M; Lam WL; Zhang L; Corbett KK; Rosin MP
Oral Oncol; 2014 Dec; 50(12):1123-30. PubMed ID: 25240917
[TBL] [Abstract][Full Text] [Related]
9. The repressive effect of miR-148a on TGF beta-SMADs signal pathway is involved in the glabridin-induced inhibition of the cancer stem cells-like properties in hepatocellular carcinoma cells.
Jiang F; Mu J; Wang X; Ye X; Si L; Ning S; Li Z; Li Y
PLoS One; 2014; 9(5):e96698. PubMed ID: 24806207
[TBL] [Abstract][Full Text] [Related]
10. ATP-binding cassette, subfamily G (ABCG family).
Kusuhara H; Sugiyama Y
Pflugers Arch; 2007 Feb; 453(5):735-44. PubMed ID: 16983557
[TBL] [Abstract][Full Text] [Related]
11. Molecular pharmacology of ABCG2 and its role in chemoresistance.
Stacy AE; Jansson PJ; Richardson DR
Mol Pharmacol; 2013 Nov; 84(5):655-69. PubMed ID: 24021215
[TBL] [Abstract][Full Text] [Related]
12. Two stem cell markers, ATP-binding cassette, G2 subfamily (ABCG2) and BMI-1, predict the transformation of oral leukoplakia to cancer: a long-term follow-up study.
Liu W; Feng JQ; Shen XM; Wang HY; Liu Y; Zhou ZT
Cancer; 2012 Mar; 118(6):1693-700. PubMed ID: 22009787
[TBL] [Abstract][Full Text] [Related]
13. Detection of CD133, Bmi-1, and ABCG2 in ameloblastic tumors.
Kumamoto H; Ohki K
J Oral Pathol Med; 2010 Jan; 39(1):87-93. PubMed ID: 19659474
[TBL] [Abstract][Full Text] [Related]
14. Podoplanin and ABCG2: malignant transformation risk markers for oral lichen planus.
Shi P; Liu W; Zhou ZT; He QB; Jiang WW
Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):844-9. PubMed ID: 20200437
[TBL] [Abstract][Full Text] [Related]
15. Expression patterns of cancer stem cell markers ALDH1 and CD133 correlate with a high risk of malignant transformation of oral leukoplakia.
Liu W; Wu L; Shen XM; Shi LJ; Zhang CP; Xu LQ; Zhou ZT
Int J Cancer; 2013 Feb; 132(4):868-74. PubMed ID: 22782852
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
